Feb 9, 2010	09:36	ICR and NASDAQ OMX to Host IPO Summit
		ICR, a leading financial communications consulting firm specializing in investor relations, corporate communications and digital media, and The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ), the world's largest exchange company, today announced they will host a U.S. IPO Summit on Wednesday, March 3, 2010, at the St. Regis Beijing.   continued...
Feb 9, 2010	09:16	PMFG, Inc. Postpones Conference Call and Earnings Release
		PMFG, Inc. (Nasdaq:PMFG), (parent of Peerless Mfg. Co.), today announced that it will postpone the release of its results of operations for the second quarter and the related conference call which was previously scheduled for Tuesday, February 9, 2010, at 10:00 a.m. Eastern while it resolves an accounting issue related to the calculation of the fair value of the embedded derivative features of our preferred stock issuance dated September 4, 2009. PMFG expects to set a new date for the conference call as soon as the results of operation are available for public release.  continued...
Feb 9, 2010	09:15	Camelot Distribution Group Unveils European Film Market Line-Up
		Camelot Entertainment Group, Inc. (OTCBB:CMGR) ("Camelot") announced today that Camelot Distribution Group ("CDG") has released its line-up for the European Film Market ("EFM"). CDG President Jamie Thompson and V.P. of Sales and Distribution Jeffrey Giles will be representing Camelot at the market, which takes place in Berlin, Germany, February 11-20, 2010. In addition to the CDG slate of films, Camelot's DarKnight Pictures will also be presenting its previously announced roster of films at EFM.  continued...
Feb 9, 2010	09:03	Nabi Biopharmaceuticals Announces Mailing of Definitive Proxy Statement
		Nabi Biopharmaceuticals (Nasdaq:NABI) (the "Company") announced today that it has commenced mailing its definitive proxy statement to stockholders for approval of the exclusive option and license agreement ("the NicVAX agreement") between the Company and GlaxoSmithKline Biologicals S.A. dated as of November 13, 2009 and the transactions contemplated thereby. The Company has scheduled a special meeting of stockholders for Tuesday, March 2, 2010 at 10:00 a.m. (EST) at the Bethesda Marriott, 5151 Pooks Hill Road in Bethesda, Maryland, to consider and vote on the NicVAX agreement and the transactions contemplated thereby. Stockholders of record as of the close of business on January 25, 2010 will be entitled to vote at the special meeting.  continued...
Feb 9, 2010	09:00	Pinnacle Foods Signs Procurement Outsourcing Agreement With ICG Commerce to Drive Cost Reductions
		As part of an initiative to reduce costs and drive margin improvement, Pinnacle Foods Group, a consumer products company famous for brands such as Vlasic, Mrs. Butterworth's and Duncan Hines, has signed a three-year contract with ICG Commerce, the procurement outsourcing specialist. ICG Commerce will support Pinnacle with spend management across a range of categories, the largest of which include advertising, logistics, capital equipment, and plant-related supplies and services.   continued...
Feb 9, 2010	09:00	Shepherd, Smith, Edwards & Kantas, LLP Defeats Motions to Dismiss Filed by Defendants in $200 Million Synthetic CDO Case
		The law firm of Shepherd, Smith, Edwards & Kantas, LLP (www.sseklaw.com) announces that the firm and its Milwaukee, Wisconsin based co-counsel, Kravit, Hovel & Krawczyk, SC, defeated Motions to Dismiss filed by the Royal Bank of Canada and Stifel Nicolaus & Co., Inc. A Milwaukee judge has ruled that claims filed by five Wisconsin school districts and their Other Post Employment Benefits ("OPEB") Trusts can go forward against the investment banks that district officials say misled them to invest two hundred million dollars into risky investments using mostly borrowed money.  continued...
Feb 9, 2010	09:00	PuraMed BioScience Secures up to $7.5 Million Funding Commitment From Southridge Partners II, Ltd.
		PuraMed BioScience (OTCBB:PMBS), a pharmaceutical company engaged in the development and marketing of a line of revolutionary, new, non-prescription medicines that treat migraine headaches, insomnia and tension-type headaches under the brand name LipiGesic(tm), announced today that it has recently secured an Equity Credit Agreement of up to $7,500,000, over the course of 24 months, which will allow the Company to initiate further efforts to reach its goals and objectives as outlined in its business plan.  continued...
Feb 9, 2010	09:00	OLB Group Announces Facebook and Twitter Implementation for the ShopFast Application Portal
		OLB Group, Inc. (OTCBB:OLBG), an e-commerce service provider offering software products and services designed to help businesses sell products over the internet, announced today that the company is implementing Facebook and Twitter setup for every store owner in the ShopFast network. Store owners will be able to market their product over social networks.  continued...
Feb 9, 2010	09:00	Skymark Research Initiates Independent Research Coverage on Phoenix Companies, Inc.
		Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Phoenix Companies, Inc. (NYSE:PNX)  continued...
Feb 9, 2010	09:00	Skymark Research Initiates Independent Research Coverage on Standard Pacific Corp.
		Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Standard Pacific Corp. (NYSE:SPF).  continued...
Feb 9, 2010	09:00	Lithera Successfully Completes Phase I Clinical Trial of LIPO-102
		Lithera, Inc. today announced the successful completion of a three-part Phase I clinical trial of LIPO-102 being developed for the treatment of thyroid-related (Graves' Disease) exophthalmos. LIPO-102 is a novel, minimally-invasive, non-ablative approach to localized fat reduction comprising an injectable aqueous combination of salmeterol xinafoate (SX) and fluticasone propionate (FP). This Phase I clinical study, carried out in abdominal adipose tissue serving as a surrogate for orbital adipose tissue, established the safety and pharmacokinetics of LIPO-102 at maximal doses within the 505(b)(2) threshold for a previously FDA-registered drug product. This trial also provided preliminary evidence of efficacy showing dose-related reductions in waist circumference measurements over the multiple dose part of the trial. A reduction of ~3 cm in mean waist circumference was observed (p=0.014).   continued...
Feb 9, 2010	09:00	Liberty Analytics Co. Initiates Independent Research Coverage on NexMed, Inc.
		Liberty Analytics Co., a leading provider of large, small - and micro-cap independent investment research, today initiated coverage on NexMed, Inc. (Nasdaq:NEXM).  continued...
Feb 9, 2010	09:00	Liberty Analytics Co. Initiates Independent Research Coverage on Strategic Hotels & Resorts, Inc.
		Liberty Analytics Co., a leading provider of large, small- and micro-cap independent investment research, today initiated coverage on Strategic Hotels & Resorts, Inc. (NYSE:BEE). Liberty Analytics is currently offering a complimentary trial subscription. To view our research go to: www.libertyanalyticsco.com.  continued...
Feb 9, 2010	09:00	Skymark Research Initiates Independent Research Coverage on Xstrata plc.
		Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Xstrata plc (Pink Sheets:XSRAY). Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com  continued...
Feb 9, 2010	09:00	Skymark Research Initiates Independent Research Coverage on NXT Nutritionals Holdings, Inc.
		Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on NXT Nutritionals Holdings, Inc. (OTCBB:NXTH).  continued...
More >>

Total: 15

* all times are in the U.S. Eastern Time Zone